Motif Bio prices U.S. IPO, EU offering to save antibiotic PhIII

Motif Bio is raising $25 million to finish its Phase III trial

Motif Bio has put together a financing package to give it the money to wrap up a Phase III trial of its antibiotic iclaprim. The agreement will see Motif Bio list on Nasdaq at the second attempt if it can sell at least 20 million shares through a placement in Europe.

London, U.K.-based Motif Bio sent out a distress signal late last month. At that time, the company’s liabilities exceeded its money by $4 million (€3.8 million), raising doubts about whether it had the means to finish a Phase III acute bacterial skin and skin structure infection trial. The situation arose after Motif Bio’s attempts in 2016 to list on Nasdaq and offload the ex-U.S. rights to iclaprim failed to yield a bank-balance-boosting deal.

Motif Bio now has the makings of such a deal. The first step is to place at least 20 million shares and 10 million warrants in Europe. Motif Bio said investors have expressed an interest in buying this many shares and warrants.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

If Motif Bio can pull off the European placement, it will push ahead with a Nasdaq IPO. Motif Bio has priced combinations of 2.4 million U.S. shares and 1.2 million warrants at $6.98. But the offering will only go ahead if Motif Bio completes the European placement. Invesco Asset Management has agreed to buy 45% of the U.S. shares and warrants, giving Motif Bio the sort of insider support that helps get IPOs done. The original Nasdaq IPO plan had Invesco buying 25% of the proposed $35 million listing.

Motif Bio has scaled back its ambitions since then. The U.S. and European listings will generate $25 million, a sum that falls to $20.5 million after underwriting discounts and commissions are subtracted. Motif Bio thinks $20.5 million will enable it to keep the lights on until it finishes one of its two Phase III trials. Beyond that, Motif Bio will once again need to raise money, but, if the Phase III is a success, it will be in a stronger position to do so.

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.